Tetsuya Effects on CD 36 Expression and HDL Knockout Mice : Pleiotropic − Troglitazone Inhibits Atherosclerosis in Apolipoprotein

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice.

  2000cited by this paper
• Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

  2000cited by this paper
• Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma.

  2000cited by this paper
• CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta.

  1999cited by this paper
• Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice.

  1999cited by this paper
• The peroxisome proliferator‐activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function

  1999cited by this paper
• Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction.

  1999cited by this paper
• Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1.

  1998cited by this paper
• PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats.

  1998cited by this paper
• PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

  1998cited by this paper
• Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ

  1998cited by this paper
• Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.

  1997cited by this paper
• Regulation of apo A-I gene expression by fibrates.

  1997cited by this paper
• Vascular Biology of CD36: Roles of this New Adhesion Molecule Family in Different Disease States

  1997cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• Inhibition of oxidation of low density lipoprotein by troglitazone.

  1996cited by this paper
• PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.

  1996cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis

  1995cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.

  1995cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat

  1994cited by this paper
• Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.

  1994cited by this paper
• CD36 is a receptor for oxidized low density lipoprotein.

  1993cited by this paper
• Antihypertensive effects of CS-045 treatment in obese Zucker rats.

  1993cited by this paper
• Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

  1992cited by this paper
• Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.

  1991cited by this paper
• Insulin and atheroma. 20-yr perspective.

  1990cited by this paper
• High-density lipoprotein--the clinical implications of recent studies.

  1989cited by this paper
• Insulin Directly Reduces Platelet Sensitivity to Aggregating Agents: Studies In Vitro and In Vivo

  1988cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988cited by this paper
• Growth-Promoting Effects of Diabetes and Insulin on Arteries: An In Vivo Study of Rat Aorta

  1986cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper

• Expression in Vascular Cells Peroxisome Proliferator-Activated Receptors and Atherogenesis : Regulators of Gene

  2004cites this paper
• The clinical significance of PPARα and γ agonism

  2002cites this paper